The Heart -- Barcelona, Spain - Out to five years, rates of target lesion revascularization (TLR) are “stable and durable” for the Endeavor zotarolimus-eluting stent (Medtronic) and adverse event rates remain low, a new pooled analysis of all studies within the Endeavor program show.
